Daré Bioscience Inc (DARE) has shared an announcement.
Daré Bioscience, Inc. has entered into royalty purchase agreements with XOMA, receiving an initial $22 million payment with the potential for additional contingent payments based on revenue milestones. These agreements involve the sale of Daré’s rights to royalties and milestone payments from its licensing agreements on products such as XACIATO™, a vaginal gel, and the future sales of Ovaprene, a contraceptive, and Sildenafil Cream, for female sexual arousal disorder. XOMA also has the option to retire Daré’s payment obligations under a separate financing agreement, further solidifying its interest in the successful commercialization of Daré’s product portfolio.
See more data about DARE stock on TipRanks’ Stock Analysis page.
